Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025.
2 Potentially High-Reward Growth Stocks to Buy Right Now
Growth stocks have been the U.S. market's primary value driver since 2008. Biotechnology equities, however, have been in a wilderness period since the central bank ramped up interest rates.
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
